
Paul J Fairchild

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4281403/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 879-883.	3.3	487
2	Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20920-20925.	7.1	176
3	Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunological Reviews, 2003, 196, 109-124.	6.0	129
4	Immune privilege induced by regulatory T cells in transplantation tolerance. Immunological Reviews, 2006, 213, 239-255.	6.0	127
5	Dendritic cells and prospects for transplantation tolerance. Current Opinion in Immunology, 2000, 12, 528-535.	5.5	94
6	Induction of Regulatory T Cells and Dominant Tolerance by Dendritic Cells Incapable of Full Activation. Journal of Immunology, 2007, 179, 967-976.	0.8	86
7	Generation of Anergic and Regulatory T Cells following Prolonged Exposure to a Harmless Antigen. Journal of Immunology, 2004, 172, 5900-5907.	0.8	80
8	Embryonic stem cells and the challenge of transplantation tolerance. Trends in Immunology, 2004, 25, 465-470.	6.8	73
9	The challenge of immunogenicity in the quest for induced pluripotency. Nature Reviews Immunology, 2010, 10, 868-875.	22.7	72
10	IL-10-Conditioned Dendritic Cells, Decommissioned for Recruitment of Adaptive Immunity, Elicit Innate Inflammatory Gene Products in Response to Danger Signals. Journal of Immunology, 2004, 172, 2201-2209.	0.8	65
11	Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regenerative Medicine, 2009, 4, 513-526.	1.7	61
12	Thymic Dendritic Cells: Phenotype and Function. International Reviews of Immunology, 1990, 6, 187-196.	3.3	50
13	The adaptive immune response to cardiac injury—the true roadblock to effective regenerative therapies?. Npj Regenerative Medicine, 2017, 2, 19.	5.2	49
14	Harnessing the properties of dendritic cells in the pursuit of immunological tolerance. Biomedical Journal, 2017, 40, 80-93.	3.1	48
15	Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141+ Subset. Frontiers in Immunology, 2017, 8, 1935.	4.8	48
16	A Role for Regulatory T Cells in Acceptance of ESC-Derived Tissues Transplanted Across an Major Histocompatibility Complex Barrier A. Stem Cells, 2010, 28, 1905-1914.	3.2	43
17	Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. Journal of Clinical Investigation, 2004, 113, 1754-1762.	8.2	36
18	Embryonic stem cells: a novel source of dendritic cells for clinical applications. International Immunopharmacology, 2005, 5, 13-21.	3.8	31

Paul J Fairchild

#	Article	IF	CITATIONS
19	Haplobanking induced pluripotent stem cells for clinical use. Stem Cell Research, 2020, 49, 102035.	0.7	30
20	Embryonic stem cells: protecting pluripotency from alloreactivity. Current Opinion in Immunology, 2007, 19, 596-602.	5.5	27
21	Approaches for immunological tolerance induction to stem cell-derived cell replacement therapies. Expert Review of Clinical Immunology, 2010, 6, 435-448.	3.0	25
22	Harnessing dendritic cells for the induction of transplantation tolerance. Current Opinion in Organ Transplantation, 2009, 14, 344-350.	1.6	24
23	Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy. Stem Cells, 2020, 38, 67-79.	3.2	22
24	Stable lines of genetically modified dendritic cells from mouse embryonic stem cells. Transplantation, 2003, 76, 606-608.	1.0	21
25	Probing Dendritic Cell Function by Guiding the Differentiation of Embryonic Stem Cells. Methods in Enzymology, 2003, 365, 169-186.	1.0	18
26	Pharmacological manipulation of dendritic cells in the pursuit of transplantation tolerance. Current Opinion in Organ Transplantation, 2011, 16, 372-378.	1.6	15
27	Therapeutic aspects of tolerance. Current Opinion in Pharmacology, 2001, 1, 392-397.	3.5	14
28	Transplantation tolerance in an age of induced pluripotency. Current Opinion in Organ Transplantation, 2009, 14, 321-325.	1.6	14
29	Cell Replacement Therapy and the Evasion of Destructive Immunity. Stem Cell Reviews and Reports, 2005, 1, 159-168.	5.6	13
30	Evasion of Pre-Existing Immunity to Cas9: a Prerequisite for Successful Genome Editing In Vivo?. Current Transplantation Reports, 2019, 6, 127-133.	2.0	13
31	Differentiation of Dendritic Cells from Human Embryonic Stem Cells. Methods in Molecular Biology, 2011, 767, 449-461.	0.9	13
32	Presentation of antigenic peptides by products of the major histocompatibility complex. Journal of Peptide Science, 1998, 4, 182-194.	1.4	12
33	Beneath the sword of Damocles: regenerative medicine and the shadow of immunogenicity. Regenerative Medicine, 2016, 11, 817-829.	1.7	11
34	Extrathymic signals regulate the onset of T cell repertoire selection. European Journal of Immunology, 2000, 30, 1948-1956.	2.9	10
35	Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy. Expert Review of Clinical Immunology, 2012, 8, 547-555.	3.0	10
36	Genetic Modification of Dendritic Cells Through the Directed Differentiation of Embryonic Stem Cells. Methods in Molecular Biology, 2007, 380, 59-72.	0.9	8

Paul J Fairchild

#	Article	IF	Citations
37	Reversal of Immunodominance Aong Autoantigenic T-cell Epitopes. Autoimmunity, 1999, 30, 209-221.	2.6	7
38	Rapamycin Conditioning of Dendritic Cells Differentiated from Human ES Cells Promotes a Tolerogenic Phenotype. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-11.	3.0	7
39	Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy. Regenerative Medicine, 2015, 10, 275-286.	1.7	6
40	Boosting Antitumour Immunity through Targeted Delivery of Interferon-α. Trends in Molecular Medicine, 2019, 25, 935-937.	6.7	1
41	Mitigating the Risk of Immunogenicity in the Pursuit of Induced Pluripotency. , 2013, , 77-94.		Ο
42	Defining and Overcoming the Immunological Barriers to Stem Cell Therapies. , 2008, , 59-80.		0